Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract: A vehicle sensor apparatus including a mounting bracket including a base portion including a mounting portion to mount the mounting bracket to a surface; a first wall portion extending from a first peripheral side of the base portion by a first distance; and a second wall portion extending from a second peripheral side of the base portion by a second distance, the first peripheral side different than the second peripheral side, wherein the base, the first wall portion, and the second wall portion define a compartment; and an object sensor disposed in the compartment and coupled to the base portion at a sensor receiving portion, wherein the mounting bracket is mountable to the surface in at least two orientations, wherein the object sensor is couplable to the mounting bracket in at least two orientations, and wherein a thickness of the object sensor is less than the first and second distances.

Abstract: An assembly includes elongated foamed elements that are arranged next to one another in one plane and bonded to one another at abutting side faces thereof, wherein the elongated foamed elements have been made by cutting at least one foamed sheet having a top and bottom surface, the at least one foamed sheet having been prepared by a foamed extrusion process and comprises a polymer composition including polypropylene, wherein the cutting is perpendicular to the top and bottom surfaces of the at least one foamed sheet, wherein the assembly has a top and bottom surface formed of surfaces of the elongated foamed elements perpendicular to the top or bottom surface of one of the at least one foamed sheet from which the respective elongated foamed element has been made, wherein the assembly is a sheet having a compression stress at yield in the thickness direction of at least 100 kPa.

Abstract: A multilayer composite includes a core layer having an assembly and a first cover layer on the core layer, the first cover layer including a first composition having a density of at least 0.903 g/cm3 and including polypropylene, wherein the first cover layer comprises a first composition having a density of at least 0.

Abstract: The present invention relates to a polyethylene composition comprising a) a polyethylene blend comprising from 95.5% to 99.5 wt % low density polyethylene (LDPE) and from 0.5% to 4.5 wt % high density polyethylene (HDPE), wherein the wt % (% by weight) is based the total amount of low density polyethylene and high density polyethylene in the blend, and b) a mixture of glycerol-mono-stearate and glycerol-mono-palmitate.

Abstract: A system for delivering energy to implanted devices using electromagnetic wireless charging and associated systems and methods are disclosed herein. In some embodiments, the system includes an energy transmission device and an implanted device. The energy transmission device can include multiple transmission coils, while the implanted device can include one or more receiving coils and one or more chargeable energy storage components. The transmission coils on the energy transmission device can each be energized to generate an electromagnetic field. When the implanted device is positioned within range of the energy transmission device, the receiving coils in the implanted device interact with the electromagnetic fields to generate a current. The current is used to charge the energy storage components.

Abstract: A polymer composition contains A) a high melt strength polypropylene in an amount ?30 wt % and ?90 wt % based on the polymer composition, B) an ethylene-based elastomer having a density ?855 to ?913 kg/m3, wherein the density is determined in accordance with ASTM D792 (2008), wherein the ethylene-based elastomer is present in the polymer composition in an amount ?10 wt % and ?49 wt % based on the polymer composition and C) a further polypropylene, wherein the further polypropylene is present in the polymer composition in an amount ?0 wt % and ?60 wt % based on the polymer composition and wherein the sum of the weight of high melt strength polypropylene and the further polypropylene is ?51 wt % based on the sum of the weight of the high melt strength polypropylene, the further polypropylene and the ethylene-based elastomer.

Abstract: The invention relates to a foamed sheet comprising a polymer composition comprising a high melt strength polypropylene wherein the high melt strength polypropylene has a melt strength?45 cN, preferably ?50 cN, more preferably ?55 cN, even more preferably ?60 cN, most preferably ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2.

Abstract: The invention relates to a high melt strength polypropylene composition comprising a high melt strength polypropylene and wherein the high melt strength polypropylene composition has a melt strength ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2.

Abstract: High melt strength polypropylene composition, wherein the high melt strength polypropylene composition comprises a high melt strength polypropylene, wherein the high melt strength polypropylene composition has a melt strength ?45 cN, more preferably ?50 cN, more preferably ?55 cN, even more preferably ?60 cN, even more preferably ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2 and wherein the high melt strength polypropylene composition has a melt flow rate ?1.0 and ?4.0 g/10 min as determined in accordance with ASTM D1238 (2013) at a temperature of 230° C. under a load of 2.16 kg.

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Abstract: High melt strength polypropylene composition, wherein the high melt strength polypropylene composition comprises a high melt strength polypropylene, wherein the high melt strength polypropylene composition has a melt strength ?45 cN, more preferably ?50 cN, more preferably ?55 cN, even more preferably ?60 cN, even more preferably ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2 and wherein the high melt strength polypropylene composition has a melt flow rate ?1.0 and ?4.0 g/10 min as determined in accordance with ASTM D1238 (2013) at a temperature of 230° C. under a load of 2.16 kg.

Abstract: The invention relates to a high melt strength polypropylene composition comprising a high melt strength polypropylene and wherein the high melt strength polypropylene composition has a melt strength ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2.

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract: A polymer composition includes a) ?10 wt % and ?60 wt % of a high melt strength polypropylene, b) ?10 wt % and ?35 wt % of a polyethylene, c) ?10 wt % and ?60 wt % of a first polypropylene, wherein the first polypropylene is chosen from the group of propylene homopolymers, propylene copolymers and/or mixtures thereof, and d) ?0 wt % and ?60 wt % of a second polypropylene, wherein the sum of the high melt strength polypropylene, the first polypropylene and the second polypropylene is ?60 wt % based on the sum of the weight of the high melt strength polypropylene, the polyethylene, the first polypropylene and the second polypropylene. The polyethylene has a density ?940 kg/m3 and ?970 kg/m3 as determined according to ISO 845 (2006).

Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.